Predicting the risk of recurrent venous thromboembolism (VTE)

Size: px
Start display at page:

Download "Predicting the risk of recurrent venous thromboembolism (VTE)"

Transcription

1 J Thromb Thrombolysis (2015) 39: DOI /s Predicting the risk of recurrent venous thromboembolism (VTE) Michael B. Streiff Published online: 27 February 2015 Ó Springer Science+Business Media New York 2015 Abstract To optimize patient outcomes with anticoagulation for venous thromboembolism (VTE), it is essential to assess patients for their recurrence risk. In this article, I will review the impact of clinical and laboratory risk factors for recurrent VTE. The presence or absence of VTE risk factors at the time of the index thrombotic event provides important information regarding recurrence risk. Patients with potent situational risk factors for thrombosis (e.g., surgery) are at low risk for recurrence while patients suffering unprovoked events are at high risk for recurrence. The presence of non-surgical clinical risk factors place patients at intermediate recurrence risk. Other clinical risk factors of variable recurrence potential include age, sex, cancer, pregnancy/puerperium, hormonal therapy and obesity. Laboratory risk factors for recurrence include thrombophilia, D dimer and other global coagulation assays as well as residual venous obstruction. Several multivariate VTE risk assessment models have been developed that combine clinical and laboratory risk factors of recurrence. If validated, these risk scores may allow for personalized anticoagulation therapy tailored to patients individual recurrence risk. Keywords Venous thromboembolism Recurrence Risk factors D dimer Risk assessment models M. B. Streiff (&) Division of Hematology, Department of Medicine and Pathology, Johns Hopkins Medical Institutions, 1830 E. Monument Street, Suite 7300, Baltimore, MD 21205, USA mstreif@jhmi.edu Introduction To optimize outcomes, it is essential to customize the duration of therapy based upon the patient s individual risk for recurrent VTE and bleeding during anticoagulation. In this paper, I will review clinical and laboratory characteristics as well as prediction models that have been used to estimate recurrence risk and discuss my current approach to VTE recurrence risk assessment when caring for a patient with a first episode of VTE. Situational prothrombotic triggers and VTE recurrence risk The most straight forward approach to estimating recurrence risk is to identify the presence or absence of situational prothrombotic triggers present at the time of a patient s thrombotic event. This approach to recurrence estimation is based upon observational studies such as Trevor Baglin s landmark 2003 Lancet publication. He and his colleagues prospectively followed a cohort of 570 consecutive patients with a first episode of symptomatic VTE. Patients with malignancy and antiphospholipid syndrome (APS) were excluded. The median age of the cohort was 67 years (range years) and 251 (44 %) participants were men. After 2 years of follow up, none of the 86 patients who suffered VTE in association with a recent surgery (VTE within in 6 weeks of surgery) had developed recurrent VTE. In contrast, 32 of 196 patients (19.4 %, 95 % confidence interval (CI) %) with unprovoked VTE and 21 of 279 patients (8.8 %, 95 % CI %) with non-surgical risk factors suffered recurrent VTE. Patients with surgically-provoked VTE were at lower risk for recurrence while patients with unprovoked VTE were at

2 354 M. B. Streiff 2.2-fold higher risk of recurrence than patients with nonsurgically provoked events [1]. The findings of the Baglin et al. study have been corroborated by several other studies [2 4]. Iorio and coworkers conducted a systematic review of 15 prospective cohort studies and randomized controlled trials of patients with a first symptomatic VTE. The risk of recurrence for patients with a surgical risk factor following completion of anticoagulation was 0.7 % per patient year while the risk of recurrence for patients with a non-surgical risk factor was 4.2 % per patient year. Among patients with unprovoked VTE the risk of recurrence was 7.4 % per patient year [5]. These studies establish the importance of considering situational pro-thrombotic triggers when estimating the risk of recurrence. Patients with a surgical trigger are at sufficiently low risk of recurrent VTE that the bleeding risks of extended duration anticoagulation are not warranted by the risk of recurrence in the absence of anticoagulation. In contrast, the risk of recurrence associated with persistent non-surgical triggers and unprovoked VTE is sufficiently great that consideration of longer duration therapy is appropriate. However, even among patients with unprovoked VTE, a substantial proportion of patients do not suffer recurrent VTE even after years of follow up. Paolo Prandoni and colleagues followed 1626 consecutive patients for up to 10 years after a first episode of VTE. The adjusted hazard of recurrent VTE was 2.3 (95 % CI ) in patients with unprovoked VTE. However, at 10 years of follow up after discontinuation of AC only 52.6 % of patients had suffered recurrent VTE [2]. Therefore, clearly all patients with unprovoked VTE do not benefit from indefinite AC and further risk stratification is required to target therapy to the patients most likely to benefit. Thrombophilia Thrombophilia has long been considered a risk factor for initial VTE. However, the influence of thrombophilia on the risk of recurrent VTE is less. In a systematic review of the literature, Segal et al. noted that factor V Leiden (FVL) heterozygosity is associated with a modest risk of recurrence (OR 1.56; 95 % CI ) whereas FVL homozygosity results in more substantial risk (OR 2.65; 95 % CI ). Patients with prothrombin gene mutation (PGM) heterozygosity had a lower recurrence risk (OR 1.45, 95 % CI ) and insufficient data existed to assess the impact of PGM homozygosity [6]. In a retrospective family cohort study of patients with known thrombophilic defects, family members with antithrombin (AT), protein C (PC) and protein S (PS) deficiency experienced a cumulative recurrence rate of 19 % at 2 years, 40 % at 5 years and 55 % at 10 years after discontinuation of anticoagulation for an annual incidence of recurrence of 6.23 % (95 % CI ). There was no difference in recurrence rates for patients with provoked or unprovoked events. In contrast, the cumulative recurrence rate among patients with FVL, PGMor elevated factor VIII levels was 7 % at 2 years, 11 % at 5 years and 25 % at 10 years after discontinuation of anticoagulation for an annual incidence of recurrent VTE of 2.25 % (95 % CI ). Interestingly, no difference in recurrence rates was noted for patients with idiopathic or provoked events. Patients with elevated factor IX, factor XI and hyperhomocysteinemia were not at increased risk for initial or recurrent VTE [7]. The data from this large family cohort study indicate that the risk of recurrent VTE varies with different thrombophilic states. Patients with potent thrombophilic defects (AT, PC, and PS deficiency) were at an increased risk of recurrent VTE. In contrast, moderate thrombophilic defects (FVL or PGM heterozygosity or elevated FVIII levels) and mild thrombophilic defects (factor IX, XI and hyperhomocysteinemia) were not at substantially increased risk for recurrent VTE. It is important to recognize the limitations of these data. By their nature, family studies may not necessarily be generalizable to all patients with a given thrombophilic defect as the individual genetic background influences the phenotypic expression of these mutations. Therefore, it is conceivable that the families examined in this study may have other unknown genetic characteristics that influenced their risk of recurrence compared to patients in the general population. It is likely that the variable penetrance of genetic thrombophilic states reflects the combined impact of multiple procoagulant and anticoagulant factors that influence the hemostatic balance of an individual. The impact of thrombophilia on outcome has also been examined in prospective observational studies and randomized controlled trials of anticoagulation. Baglin et al. tested patients for FVL, PGM, AT, PC and PS after discontinuation of anticoagulation. The presence of FVL (HR 1.35, 95 % CI ; p = 0.417), PGM (HR 1.74 [95 % CI ]; p = ) or any form of heritable thrombophilia did not increase the risk of recurrent VTE (HR 1.50, 95 % CI ; p = 0.187) (Table 1) [1]. In the MEGA study, Christiansen et al. included 474 consecutive patients with a first objective episode of DVT at least 3 months after discontinuation of anticoagulation. Testing for FVL, PGM, AT, PC, PS, factor VIII, IX, XI, fibrinogen and homocysteine was performed a median of 19 months after the thrombotic event. Two hundred fiftynine patients (55 %) had idiopathic DVT (absence of pregnancy/puerperium, oral contraceptive use within 30 days or surgery, trauma, immobilization or plaster cast within 3 months). Patients older than 70 years or with

3 Risk of recurrent VTE 355 Table 1 The impact of thrombophilia on the risk of recurrent VTE Study Patients Duration of follow up (months) Thrombophilia Number of affected patients/total patients (%; 95 % CI) Recurrent VTE (hazard ratio [95 % CI]) Baglin et al. [1] 570 first VTE 24 FVL 77/487 (16 %; ) F2 20/476 (4 %; ) AT 8/485 (2 %; ) PC 5/431 (1 %; ) PS 27/428 (6 %; ) Christiansen et al. [4] 474 first DVT 87 FVL 92/474 (19 %) F2 29/474 (6 %) AT, PC, PS deficiency 25/474 (5 %) F8 110/474 (23 %) F9 86/474 (18 %) F11 92/474 (19 %) Fib 87/474 (18 %) HC 83/474 (18 %) Prandoni et al. [2] 1626 first VTE 50 FVL 111/953 (11.6 %) F2 45/953 (4.7 %) AT 7/953 (0.7 %) PC 16/953 (1.7 %) PS 14/953 (1.5 %) LA 23/953 (2.4 %) Santamaria et al. [8] 267 first proximal DVT 47 FVL 15 (7.7 %) F2 14 (7.2 %) AT 3 (1.5 %) PC 2 (1.0 %) PS 2 (1.0 %) APS 4 (2.1 %) HC 7 (3.6 %) Ribierio et al. [9] 378 first VTE 43 FVL 37 (10 %) F2 20 (6 %) F8 47 (14 %) HC 13 (4 %) ABO Non-O 190 (73 %) 15 % versus 10 % (HR 1.50 [ ]) 28 versus 22 per 1000 pt.-years. (HR 1.4 [ ]) HR 2.02 ( ) HR 1.78 ( ) IRR 1.6 ( ) FVL factor V Leiden, F2 factor 2 gene mutation, AT antithrombin deficiency, PC protein C deficiency, Protein S protein S deficiency, F8 elevated factor VIII activity, F9 elevated factor IX antigen, F11 elevated factor XI antigen, Fib elevated fibrinogen, LA lupus anticoagulant, APS antiphospholipid syndrome, HC hyperhomocysteinemia malignancies were excluded. During 7.3 years of follow up, 90 patients had a recurrent thrombotic event (overall incidence 25.9 per 1000 patient-years or 2.6 % per year). The cumulative incidence after 5 years was 12.4 %. No increase in recurrence risk was noted in the 319 patients who had at least 1 prothrombotic abnormality compared to those who had none (HR 1.4; 95 % CI ). Patients with more than one prothrombotic abnormality were at modestly increased risk of recurrence. (HR 1.6; 95 % CI ) No increased risk was seen for patients with FVL, PGM, elevated factor VIII, IX or XI or hyperhomocysteinemia. A trend toward increased risk was seen for the 25 patients with AT, PC or PS deficiency (HR 1.8; 95 % CI ). Patients with fibrinogen exceeding 410 mg/dl were at increased risk for recurrent VTE (HR 1.7; 95 % CI ) (Table 1) [4]. Santa Maria et al. evaluated the risk of recurrence associated with thrombophilia in 195 participants of the Warfarin Optimal Duration Italian Trial (WODIT) prospective randomized controlled trial of 3 versus 12 months of anticoagulation for a first episode of idiopathic proximal DVT. Patients with known malignancies, thrombophilia, and temporary risk factors for VTE including recent trauma, prolonged immobilization, surgery, pregnancy, delivery, puerperium, use of oral contraceptives or hormone replacement therapy were excluded. Patients

4 356 M. B. Streiff were screened for thrombophilia at the investigators discretion after the withdrawal of anticoagulation. The overall recurrence rate after 47 months of follow up was 6.2 % per patient year. Twenty of 57 patients (35.1 %) with thrombophilia and 29 of 138 patients (21 %) without thrombophilia suffered recurrent VTE for a hazard ratio of 1.78 (95 % CI ). Interestingly, the difference in recurrent VTE among patients with thrombophilia was seen solely in patients who received only 3 months of anticoagulation (HR = 3.21, 95 % CI , p = 0.008). There was no difference in recurrence in patients treated for 12 months (HR = 1.09, 95 % CI , p = 0.840). The difference in recurrence among patients with thrombophilia was due to an increased risk of recurrence among patients with acquired thrombophilia (i.e., antiphospholipid antibodies) (HR = 3.31, 95 % CI , p = 0.002) (Table 1) [8]. Prandoni et al. followed 1626 patients with a first episode of proximal DVT and/or PE for a maximum of 10 years (median 50 months). Patients were excluded if they had active cancer, an indication for long term anticoagulation or could not follow up or had a life expectancy of 6 months or less. Patients were classified as having secondary VTE if they were pregnant, had given birth within the previous 3 months, or took estrogens; if they had had a recent (less than 3 months) leg trauma, fracture, or surgical intervention; or if they had been bedridden for more than 1 week because of a chronic medical illness. All other patients were regarded as having an unprovoked episode of VTE. Thrombophilia testing (AT, PC or PS, FVL, PGM and lupus-like anticoagulants) was performed prior to initiation of anticoagulation or after its discontinuation at the direction of the participating clinicians. Three hundred and seventy-three patients (22.9 %) suffered recurrent VTE. The cumulative incidence was 11.0 % (95 % CI ) after 1 year, 19.6 % ( ) after 3 years, 29.1 % ( ) after 5 years, and 39.9 % ( ) after 10 years. The risk of recurrent VTE was twofold higher among patients with thrombophilia (HR 2.02 [95 % CI ]). Among patients with unprovoked VTE, thrombophilia was associated with an increased risk of recurrence (adjusted HR 1.91; 95 % CI ). Six of 13 patients (46.2 %; 95 % CI ) with multiple abnormalities suffered recurrent VTE as compared with 71 of 216 patients (32.9 %; 95 % CI ) with single abnormalities (Table 1) [2]. These data indicate that thrombophilia is associated with an increased risk of recurrence. In contrast to Christiansen et al. and Baglin et al., Prandoni and colleagues performed testing for lupus inhibitors which may have contributed to the positive association of thrombophilia testing and recurrent VTE. Limitations of Prandoni et al. s analysis include the fact that thrombophilia testing was only performed in 59 % of patients at the discretion of investigators, testing was not centralized and it was performed in retrospect in some patients. Ribiero and coworkers performed a prospective cohort study of 378 consecutive patients referred for a first episode of VTE to a single tertiary care hospital between April 2000 and July Two hundred ninety-one patients (78 %) were women and 253 (67 %) had a provoked event. The median age was 36 years. The median follow up was 43 months. Recurrent VTE occurred in 35 patients (9 %) for an incidence of 22 per 1000 patient-years. Patients with any thrombophilia were not at increased risk for recurrent VTE (incidence rate ratio 1.6; 95 % CI ). This result remained unchanged among patients with unprovoked (IRR 4.4; ) and provoked VTE (IRR 0.7; ) (Table 1) [9]. Limitations of this study include its small sample size, single tertiary care center study setting and a limited thrombophilia testing menu. Nevertheless the results of this study are consistent with previous studies that thrombophilia testing has a limited impact on the risk of recurrent VTE. This conclusion is also supported by several prospective cohort studies conducted to derive clinical prediction rules for recurrent VTE in patients with unprovoked VTE. Rodger et al. did not identify FVL, the PGMor homocysteine levels C15 lmol/las risk factors for recurrent VTE. In univariate analysis, antiphospholipid antibodies were associated with an increased risk of recurrence in men (relative risk (RR) 1.85; 95 % CI ) but not women (RR 0.59; ). Conversely, factor VIII C 2.0 units/ml was associated with an increased risk in women (RR 2.67; 95 % CI ) while a factor VIII C 1.55 units/ml was not associated with increased risk in men (RR 1.56; 95 % CI ) [10]. In their prospective cohort study of patients with a first unprovoked VTE, Eichinger et al. found that FVL was associated with a modest hazard ratio of 1.68 (95 % CI ) while PGM was not associated with increased risk (HR 1.0; 95 % CI ) [11]. Similarly using a pooled database of 2554 patients with first unprovoked VTE, Tosetto et al. noted no increase in the presence of thrombophilia among patients who did and did not suffer recurrent VTE during a median follow up of 22.4 months (23.4 vs %, p = 0.396) [12]. In conclusion, the collective weight of the available evidence does not support the use of inherited thrombophilia testing to determine the risk of recurrent VTE in individual patients APS has been identified as an important acquired thrombophilic state. The diagnosis of APS requires the presence of both clinical and laboratory features. Clinical manifestations of APS included 3 or more first trimester miscarriages, one or more fetal death in utero or objectively confirmed venous or arterial thrombotic events. Laboratory criteria include repeatedly positive (separated

5 Risk of recurrent VTE 357 by at least 12 weeks) lupus inhibitor testing or positive tests for cardiolipin or beta 2 glycoprotein 1 antibodies [13]. Schulman and coworkers demonstrated that the risk of recurrent VTE was twofold greater in patients with elevated titers of cardiolipin antibodies during four years of follow up (29 vs. 14 %, p = ) [14]. In a study of patients with a first episode of unprovoked VTE, Kearon and colleagues found the risk of recurrent VTE was almost fourfold higher among patients with antiphospholipid antibodies (RR 3.94; 95 % CI ) [15]. Although APS has been considered a strong risk factor for recurrent VTE and an indication for indefinite anticoagulation, the evidence basis for this conclusion is limited. In a systematic review of APS and the risk of recurrent VTE, Garcia et al. found that the quality of evidence is low [16]. Only 8 studies have been published on this topic, 6 randomized trials and 2 cohort studies. APS testing differed considerably between the studies as some studies only tested patients once, some did not specify the criteria for a positive test, the criteria for a positive test varied as did the type of antibodies investigated and the setting of laboratory testing (on vs. off anticoagulation, interval between thrombotic event and testing). The relative risk of recurrent VTE in APS patients was 1.41 (95 % CI ). The unadjusted risk ratio for cardiolipin antibody positivity was 1.53 (95 % CI ) and the risk ratio for lupus inhibitor positivity was 2.83 (95 % CI ) [16]. These data underscore the need for larger higher-quality studies. Until these data are available, I believe that it is safer to consider patients with rigorously defined APS as being at high risk for recurrent VTE and to strongly consider long term anticoagulation in these patients. Gender In 2004 Kyrle et al. published a prospective cohort study of 826 patients followed for an average of 36 months after a first episode of spontaneous VTE that demonstrated that men were 3.6-fold more likely to develop recurrent VTE than women (20 vs. 6 %; RR 3.6 [95 % CI ]) [17]. This risk remained unchanged after adjustment for age, the presence of FVL, the PGM and elevated levels of factor VIII or IX [17]. Subsequently, several other studies confirmed this observation [18, 19]. A study level metanalysis of 15 studies including 5416 patients conducted by McRae and colleagues found a relative risk of recurrent VTE of 1.6 (95 % CI 1.2 2) for men compared to women [20]. The relative risk for recurrence in men was lower in randomized trials (RR 1.3; 95 % CI ) than in observational studies (2.1; 95 % CI ). The increased recurrence risk among men remained after excluding studies that enrolled patients with hormonal risk factors (RR 1.4; 95 % CI ). Likewise, the strength of this association was not influenced by the exclusion of patients with distal DVT [20]. Douketis et al. found similar results in a more recent patient-level metanalysis of 2554 patients followed for 27 months [21]. Among patients with unprovoked VTE, men were twofold more likely to suffer recurrent VTE than women (HR 2.2; 95 % CI ). After exclusion of women with hormone-associated VTE, men remained more likely than women to suffer recurrent VTE (HR 1.8; 95 % CI ). In contrast, there was no difference in recurrence risk between men and women after a first episode of provoked VTE (HR 1.2; 95 % CI ). In women with hormone associated VTE in the absence of other risk factors, the risk of recurrence was less than in women with unprovoked VTE with no previous hormone use (HR 0.5; 95 % CI ) [21]. A recent analysis of the MEGA population-based case control study found that when reproductive and hormonal risk factors for VTE are taken into account men have a 2.1- fold higher risk of first VTE compared to women (95 % CI ) [22]. Therefore, men are at twofold greater risk of both initial and recurrent VTE. The reason for this increased risk remains unknown. These data suggest that gender is an important variable to consider when assessing the risk of recurrent VTE. Hormonal therapy and recurrent VTE Hormonal contraceptives and hormone replacement therapy increase the risk of VTE to a varying degree depending upon the dose of estrogen, the type of progestin in combined estrogen/progestin tablets and the route of administration [23]. In women who suffer a first episode of VTE associated with hormonal therapy, the recurrence rate varies depending upon whether hormonal therapy is discontinued. In the MEGA study, Christiansen et al. noted that the recurrence rate among women who discontinued hormonal therapy after a hormone-associated VTE was lower than among women who used hormonal therapy during follow up (9.7 per 1000 patient-years [95 % CI ] vs per 1000 patient-years [95 % CI ]). The rate was even higher if one focused only on the time period of hormone administration (55.3 per 1000 pt.-years (95 % CI ). They did not note a difference in recurrence rates between women with or without hormonal therapy exposure prior to their initial VTE (9.7 per 1000 patient-years [ ] vs per 1000 patient-years ( )) [4]. In the PREVENT study of low-dose warfarin therapy (INR vs. placebo), the 3 year probability of recurrent VTE was 15.0 % (95 % CI ) among the

6 358 M. B. Streiff 109 women with VTE unassociated with hormonal therapy compared to 5.0 % (95 % CI ) among the 129 women with hormone-related thrombosis. Women with hormone-related thrombosis were at a 46 % lower recurrence risk (HR 0.54; 95 % CI ) [24]. In their patient level metanalysis, Douketis et al. also found that women with hormone-associated VTE had a 50 % lower risk of recurrence than women without hormone-associated VTE (HR 0.5; 95 % CI ). When the type of hormonal therapy was specified, women with oral contraceptive-associated VTE had a lower risk of recurrence than non-hormone users (HR 0.39, 95 % CI ). The risk of recurrence among users of hormone replacement therapy was slightly less although not significant (HR 0.76, 95 % CI ) [21]. Use of hormones at the time of the index VTE was also associated with a significant reduction in recurrence in the DASH cohort [12]. If hormonal therapy is medically necessary, anticoagulation should be continued as this has been shown to be effective in preventing recurrent VTE in patients on hormonal therapy [25]. Pregnancy-associated VTE Pregnancy is associated with a 4- to 5-fold increased risk of VTE. The risk of VTE is highest in the early postpartum period but the risk remains elevated up to 6 12 weeks post-partum [26, 27]. In the absence of thromboprophylaxis, women with a previous history of pregnancy-associated VTE have a 2 10 % chance of suffering a recurrent event during pregnancy (OR 24.8; 95 % CI ) [28 30]. In an administrative database analysis, White and colleagues noted that the risk of recurrent VTE was lower among women with pregnancyassociated VTE than women with unprovoked VTE (5.8 vs %, HR 0.6; [95 % CI ] p = 0.02). However, 12 of 34 subsequent VTE among women with pregnancy-associated VTE (35 %) occurred during a subsequent pregnancy compared with 29 of 331 events among women with unprovoked VTE (8.7 %) (p \ 0.001). Overall, the incidence of recurrent VTE during subsequent pregnancies was higher in patients with pregnancy-associated VTE (21 of 465, 4.5 %) than patients with previous unprovoked VTE (37 of 1353, 2.7 %, RR = 1.7, 95 % CI ) [31]. These data indicate that women with pregnancy-associated VTE are at especially high risk for recurrence during subsequent pregnancies so thromboprophylaxis is essential. The appropriate dose of thromboprophylaxis (prophylactic, intermediate or therapeutic dose) remains to be determined although treatment failures have been noted in patients receiving prophylactic dose anticoagulation [32]. Obesity Obesity has been associated with an increased risk of initial and recurrent VTE [33 36]. In the Austrian Study of Recurrent Venous Thromboembolism, 1107 patients were followed prospectively for 46 months after completion of anticoagulation for a first episode of unprovoked VTE. Four years after discontinuation of anticoagulant therapy, the probability of recurrent VTE was 9.3 % (95 % CI %) for patients with a BMI less than 25, 16.7 % (95 % CI %) for patients with a BMI of and 17.5 % (95 % CI %) for patients with a BMI [ 30. Compared with their normal weight counterparts, the adjusted hazard ratio for recurrent VTE was 1.3 (95 % CI ) (p = 0.20) among overweight patients and 1.6 (95 % CI ) (p = 0.02) among obese individuals [36]. In a smaller prospective cohort study, Olie et al. found that obesity among women increased the risk of recurrent VTE by 2.8-fold (95 % CI ) compared with normal weight subjects [37]. These studies identify obesity as an important modifiable risk factor for recurrent VTE. Cancer Cancer is associated with a 2- to 4-fold increased risk of recurrent VTE [38, 39]. In the Olmsted County cohort, Heit et al. noted that patients with malignant disease were at 2.2-fold higher risk of recurrence than patients without cancer. Cancer patients undergoing chemotherapy had a 4.2-fold greater risk of recurrence [38]. In a prospective cohort study of 842 patients, Prandoni and colleagues noted a recurrent thrombosis rate of 20.7 % (95 % CI %) among patients with cancer versus 6.8 % (95 % CI %) for patients without cancer (HR 3.2 [95 % CI ]). The extent of cancer influenced recurrence risk. In patients with TNM stage IV, stage III, or stage I or II disease, the frequency of recurrent VTE per 100 patient-years was 54.1, 44.1, and 14.5, respectively. Compared to patients without cancer, these rates correspond to hazard ratios for recurrent VTE of 4.6 (95 % CI ), 5.3 (95 % CI ), and 1.9 (95 % CI ) [39]. Major bleeding was also more common among cancer patients. Major bleeding occurred in 12.4 % (95 % CI %) of cancer patients and 4.9 % (95 % CI %) of patients without cancer (HR 2.2 [95 % CI ]). Similar to recurrent VTE, major bleeding was associated with cancer disease burden. The frequency of major bleeding per 100 patient-years was 42.8, 19.1, and 3.4 in patients with TNM stage IV, stage III and stage I or II cancer. Compared to patients without cancer, the hazard

7 Risk of recurrent VTE 359 ratios for major bleeding was 4.8 (95 % CI ), 2.5 (95 % CI ), and 0.5 (95 % CI ) in patients with TNM stage IV, stage III and stage I or II cancer, respectively. Episodes of major bleeding were not associated with excessive anticoagulation [39]. These data in conjunction with data from other studies of cancer patients with VTE support long-term anticoagulation in patients with cancer as long as their cancer is active or undergoing therapy. To develop a VTE risk assessment model, Louzada et al. performed a retrospective cohort study of cancer patients treated for VTE at the Thrombosis unit of the Ottawa Hospital [40]. In their 543 patient cohort, 200 (36.8 %) were treated with warfarin and 343 (63.2 %) were treated with LMWH. The mean age of participants was 63 years and 240 (44 %) were males. Four hundred eighty-five patients had solid tumors (89 %) and 58 (11 %) had hematologic malignancies. Distant metastases were present in 238 patients (44 %) at the time of VTE diagnosis and 306 patients (63 %) had adenocarcinomas. Fifty-five patients (10 %) developed recurrent VTE within the first 6 months of anticoagulation. There were 19 (9.5 %) recurrent events in patients taking VKA and 36 (10.5 %) in patients taking LMWH (relative risk, 1.13; 95 % CI ; p = 0.565). Multivariate analysis identified 4 independent predictors of recurrent VTE; sex, primary tumor site, tumor stage, and prior history of VTE. Predictors associated with an increased risk of recurrence included female sex (1 point), lung cancer (1 point) and a history of previous VTE (1 point). Predictors associated with a lower risk of VTE included breast cancer (1 point) and localized disease (TNM stage I) (2 points). Patients with a score of 0 had a low risk for recurrent VTE (4.5 %) while patients with a score C1 point had a high risk for recurrence (19 %). The model was predictive of recurrence regardless of treatment (warfarin vs. LMWH). The authors validated their model using participants from the CLOT and CANTHANOX studies. Patients with a score less than 0 had a low risk of recurrence (5.1 %), patients with a score of zero had an intermediate risk (9.8 %), and patients with a score C1 had a high risk (15.8 %) (Table 2) [40]. Table 2 Ottawa prediction rule for recurrent VTE in cancer patients Risk factor Points Female sex?1 Lung cancer?1 Prior VTE?1 Breast cancer -1 Low stage (TNM stage I) -2 Low risk B 0 points, intermediate risk = 0 points, high risk = 1or more points The Ottawa Prediction rule has recently been validated in a separate patient cohort by den Exter et al. [41] They used data from a previously published, multicenter observational study of LMWH and vitamin K antagonists in the treatment of VTE in cancer patients. Similar to Louzada et al., original publication, den Exter and colleagues found that the Ottawa Prediction Rule identified patients in their cohort at low (2.4 %), intermediate (8.8 %) and high cumulative risk (15.9 %) of recurrent VTE over 6 months of follow up [41]. A limitation of both studies is the inclusion of patients who treated with vitamin K antagonists while current guidelines recommend LMWH for treatment of cancer-associated VTE. Nonetheless, these studies indicate that the Ottawa Prediction Rule could facilitate the individualized anticoagulation for cancer patients. Prospective management studies testing this hypothesis are warranted. Chee et al. recently published a retrospective analysis of the Olmsted County cohort of cancer patients who had suffered VTE between 1966 and 2000 [42]. Of the 681 patients with incident VTE and active cancer, 204 (30 %) died on the day of diagnosis or were diagnosed with VTE on autopsy, leaving 477 patients for study. The median age of the cohort was 68.9 years and 46.3 % were women. Sixty-six percent had stage IV disease and 10.7 % had stage III disease. Incident thrombotic events included 280 DVT only (including 22 arm DVT, three mesenteric vein thrombosis, three IVC thrombosis, two ovarian vein thromboses and four renal vein thromboses) and 197 PE ± DVT. During 1533 person-years of follow up, 139 patients (29 %) developed recurrent VTE (64 PE ± DVT and 75 DVT alone) and 303 (89.6 %) of the 338 who did not recur died. Independent predictors of recurrent VTE from multivariate Cox proportional hazards analysis included stage IV pancreatic cancer (HR 6.38), brain cancer (HR 4.57), myeloproliferative or myelodysplastic disorder (HR 3.49), ovarian cancer (HR 3.22), stage IV cancer (non-pancreas) (HR 2.85), lung cancer (HR 2.73), neurologic disease with paresis (HR 2.38) and cancer stage progression (HR 2.14). Patients with one or more of these risk factors had a threefold (HR 3.02; 95 % CI ; p \ 0.001) higher risk of recurrence than patients without any of these risk factors. Cancer patients without risk factors were at similar risk of recurrence as VTE patients without cancer (HR 1.4; 95 % CI ; p = 0.16) [42]. Limitations of Chee et al. s analysis include that its cohort is more than 10 years old so the outcomes and treatments of the patients may differ substantially from contemporary patient cohorts. In addition, the population of Olmsted County is predominantly white and non-latino so the results may not be generalizable to other populations. Nevertheless the Olmsted and Ottawa studies provide valuable information on risk factors for recurrent VTE in cancer patients that warrant validation in prospective management studies.

8 360 M. B. Streiff Residual vein obstruction Residual venous obstruction (RVO) at the conclusion of therapy has also been identified as a predictor of recurrent VTE [43 46]. Conceptually, residual vein occlusion is a rational and potentially biologically relevant marker for future thrombotic potential for several reasons; (1) it is a rough measure of the original thrombus burden which may be a surrogate measure of an individual s procoagulant potential, (2) it may provide an estimation of an individual patient s fibrinolytic system which may be inversely proportional to their risk of recurrent thrombus formation, (3) it provides a direct measure of residual thrombus which by slowing local blood flow may increase the risk for recurrent ipsilateral DVT. However, the prognostic value of RVO is difficult to assess as different studies have used different criteria for RVO, assessed RVO at different time points during the course of therapy and studied patient populations with different risks for recurrent VTE. Donnadini et al. performed a patient-level metanalysis of 10 studies investigating the use of RVO to assess the risk of recurrent VTE in patients after a first episode of unprovoked VTE [47]. Their analysis included 2527 patients with a median age of 65 years. There were 1106 women (44 %). RVO was detected in 1380 patients (55.1 %) a median of 6 months after diagnosis. Recurrent VTE developed in 399 patients (15.8 %) during a median follow up of 23.3 months. RVO was modestly associated with recurrent VTE (HR 1.32; 95 % CI ). RVO measured at 3 months was associated with a higher risk of recurrent VTE (HR 2.17; 95 % CI ) while RVO detected beyond 6 months was not a significant predictor of recurrence risk (HR 1.19; 95 % CI ) [47]. Therefore, the presence of RVO at the conclusion of a course of anticoagulation for unprovoked VTE is a modest predictor of recurrence risk. In my opinion, RVO is insufficiently predictive to be used alone in assessing patients risk for recurrent VTE. In combination with other risk factors, however, RVO may prove useful. Several ongoing studies are assessing the prognostic value of RVO when incorporated with other variables into a risk assessment model. Global measures of activated coagulation D dimer, a by-product of fibrinolysis of cross-linked fibrin clot has been used extensively to assess the recurrence risk of patients after a course of anticoagulation. The first major study to assess the utility of D dimer in this role was published by Palareti et al. in 2006 [48]. In the PROLONG study, Palareti and coworkers performed D dimer testing 1 month after discontinuation of anticoagulation in 608 patients who had completed at least 3 months of anticoagulation for a first episode of unprovoked VTE. D dimer was measured using the Clear view Simplify D dimer assay. 385 patients with normal D dimer levels were assigned to observation only. Two hundred twenty-three patients (36.7 %) with an abnormal D dimer were randomly assigned to anticoagulation (target INR 2 3) (N = 103) or observation (N = 120). During a mean follow up of 1.4 years, 18 of the 120 patients (15 %) with abnormal D dimer levels who stopped anticoagulation suffered recurrent VTE compared with 3 of 103 patients (2.9 %) with abnormal D dimer levels who resumed anticoagulation (HR 2.27; 95 % CI ) (p = 0.02). Recurrent VTE occurred in 24 of 385 patients (6.2 %) who had normal D dimer levels and remained off anticoagulation. This landmark study established the strategy of employing D dimer in the risk stratification of patients with unprovoked VTE [48]. This result has been verified by a number of subsequent studies. A systematic review of seven studies of D dimer assays in 1888 patients with a first episode of unprovoked VTE found that the annual risk of recurrence was 8.9 % (95 % CI %) in patients with an abnormal D dimer and 3.5 % (95 % CI %) in patients with normal D dimers [49]. Several limitations of this analysis are that different D dimer assays were used for testing in the different papers, testing was performed at different times after discontinuation of anticoagulation and the duration of anticoagulation prior to testing differed. A metanalysis performed by Bruinstroop et al. that focused solely on studies enrolling patients with a first idiopathic VTE who performed D dimer testing 1 month after discontinuation of anticoagulation noted similar results (recurrent VTE-elevated D dimer 16.6 % vs. normal D dimer 7.2 %; odds ratio 2.36 [95 % CI ]) [50]. In a patient-level metanalysis of seven studies with 1818 patients with unprovoked VTE, Douketis et al. found that an abnormal D dimer was associated with a hazard ratio of 2.59 (95 % CI ) for recurrent VTE. The risk of recurrent VTE was 3.7 per 100 patient years (95 % CI ) in patients with negative D dimer assays and 8.8 per 100 patient years (95 % CI ) in patients with abnormal D dimer results. Regardless of the timing of D dimer testing after discontinuation of anticoagulation (less than 3 weeks, 3 5 weeks, greater than 5 weeks), an abnormal D dimer was associated with an increased risk of recurrent VTE. Similarly, abnormal D dimer levels predicted a higher risk of recurrence regardless of age or cut point (500 vs. 250 lg/l) [51]. In the PROLONG2 study, Cosmi et al. examined the predictive values of serial D dimer tests on identification of patients at risk for recurrent VTE [52]. At the intended end of anticoagulation, patients underwent D dimer testing if

9 Risk of recurrent VTE 361 their INR was in the therapeutic range. Patients with normal D dimers discontinued anticoagulation while those with abnormal D dimers continued anticoagulation for an additional 6 months. In the group with normal D dimers at the conclusion of intended therapy, D dimer testing was repeated 30 days after discontinuation. Patients with abnormal D dimer results at this time point resumed AC while patients with normal D dimers remained off AC and underwent bimonthly D dimer testing for 1 year. The D dimer result was normal 1 month after discontinuation of anticoagulation in 243 of 355 patients (68 %). Among these 243 patients, 8 patients (3.3 %; 95 % CI 1 6 %) suffered a recurrent VTE prior to the next D dimer test on day 90. Among patients whose D dimer at day 90 was abnormal and remained persistently abnormal, the hazard ratio of recurrent VTE was ninefold higher than patients whose D dimer was normal at day 90 and remained normal thereafter (Recurrent VTE 27 per 100 patient years [95 % CI 12 48] vs. 2.9 per 100 patient years [95 % CI 1 7]; HR 9.38, p = ). Patients who developed an abnormal D dimer after day 90 and whose D dimer remained persistently abnormal thereafter were at almost fourfold greater risk of recurrent VTE than patients with persistently normal D dimers from day 90 forward (Recurrent VTE 11.1 per 100 patient years [95 % CI 4 24] vs. 2.9 per 100 patient years [95 % CI 1 6]; HR 3.78; p = 0.047) [52]. These results indicate that serial D dimer testing especially in the first 3 months after discontinuation of anticoagulation can identify a subgroup of patients with unprovoked VTE who are at low risk for recurrence. Limitations of this study included its open label design, the limited size of its subject population and the use of a qualitative D dimer test which may introduce a degree of subjectivity when assessing test results. The same research team has also investigated the utility of D dimer testing for assessment of recurrence risk in patients after a first episode of provoked VTE [53]. In 296 patients the authors performed a compression ultrasound on the day of discontinuation of anticoagulation. D dimer levels were measured on day 0 (day of anticoagulation discontinuation) and day 30 after discontinuation of anticoagulation using the VIDAS D-dimer ELISA (biomerieux, Lyon, France; cut-off 500 ng/ml). VTE were considered provoked if they were associated with surgery or trauma in the previous 3 months, prolonged immobilization or hospitalization (longer than 3 days) for an acute medical illness in the previous 3 months, current use of oral contraception or hormonal replacement therapy, ongoing pregnancy or puerperium, or prolonged travel ([4 h) in the previous 4 weeks. The median duration of anticoagulation was 5 months (range 3 37 months) for patients with DVT and 7 months (range 3 78 months) for PE. RVO was present in 44.8 % (132/294) of patients. RVO was not associated with an increased risk of recurrence (adjusted HR 1.1; 95 % CI ). An abnormal D dimer at the time of discontinuation of anticoagulation (day 0) (11.1 VTE per 100 patient-years [95 % CI 4 24] vs. 2.2 VTE per 100 patient-years [95 % CI 1 4]; adjusted HR 4.2 [ ]) and 30 days after discontinuation of anticoagulation (day 30) (6.7 VTE per 100 patient-years [95 % CI 3 12] vs. 1.5 VTE per 100 patient-years [95 % CI 0 3]; adjusted HR 3.8 [ ]) were both associated with an increased risk of recurrence [53]. This study provides evidence that D dimer testing may be of utility in assessing recurrence risk in patients with provoked VTE. Palareti et al. conducted a prospective management study using D dimer testing to determine the duration of therapy in patients who had suffered a first episode of unprovoked or provoked VTE in association with weak risk factors (minor, arthroscopic or laparoscopic surgery, pregnancy, estrogen therapy, long haul travel ([6 h), minor trauma not requiring hospitalization or plaster cast, medical hospitalization or reduce mobility (but not immobility) [54]. All participants had at least 3 months of anticoagulation. A duplex ultrasound was done of the proximal leg veins at prior to discontinuation of anticoagulation. A quantitative D dimer was done at the time of anticoagulation discontinuation (Time 0, T0). Patients with abnormal D dimer assays were instructed to continue anticoagulation. Patients with normal D dimer studies on T0 discontinued anticoagulation and performed serial D dimer assays after days (T15), (T30), (T60), and (T90) days. Patients were recommended to resume anticoagulation at the first positive D-dimer result. Age- and sex-specific cutoffs were used for D dimer assays. Of 1010 patients, anticoagulation was stopped in 528 (52.3 %) with persistently negative D-dimer who subsequently experienced 25 recurrences (3.0 % per patientyear; 95 % CI %). Of the remaining 482 patients, 373 resumed anticoagulation and 109 refused. Recurrent VTE developed in 15 patients (8.8 % per patient-year; 95 % CI ) of the latter group and in 4 of the former patients (0.7 % per patient-year; 95 % CI ; hazard ratio 2.92; 95 % CI ; p = ). Major bleeding occurred in 14 patients (2.3 % per patient-year; 95 % CI ) who resumed anticoagulation [54]. This study demonstrated that serial D dimer measurements can identify patients with unprovoked or minimally provoked VTE who are at low risk for recurrent VTE. Endogenous thrombin potential or thrombin generation Endogenous thrombin potential is another global measure of activated coagulation that has been investigated as a potential risk factor for recurrent VTE. Several different

10 362 M. B. Streiff assays have been used to measure thrombin generation including The Calibrated Automated Thrombogram Ò (Thrombinoscope BV, Maastricht, The Netherlands) and the Technothrombin Ò TGA (Technoclone, Vienna, Austria) which both use a fluorogenic substrate, and the Endogenous Thrombin Potential Assay Ò (Siemens Healthcare Diagnostic Inc., Deerfield, IL, USA) and the Pefakit Thrombin Dynamics Test Ò (Pentapharm, Basel, Switzerland) which employ a chromogenic substrate. In a prospective study of 914 patients with an unprovoked VTE who were followed for an average of 47 months, Hron et al. measured thrombin generation (TG) using the Technothrombin Ò TGAassay [55]. Blood for the assay was collected a median of 13 months (range 3 weeks to 94 months) after discontinuation of anticoagulation. VTE recurred in 100 patients. Recurrence was unprovoked in 90 patients and provoked by surgery or trauma in 10 patients. In a multivariate analysis, patients with a peak thrombin generation of less than 300 nm (nm) had a relative risk of recurrent VTE of 0.37 [95 % CI ]) compared to patients with TG greater than 400 nm. Patients with TG between 300 and 400 nm were also significantly less like to suffer recurrent VTE (RR 0.45 [95 % CI ]). After 4 years, the probability of recurrence was 6.5 % (95 % CI %) among patients with thrombin generation less than 400 nm compared with 20.0 % (95 % CI %) among patients with higher values (p = 0.001) [55]. Using the ThrombinoscopeTM Assay Ò (Thrombinoscope BV, Maastricht, The Netherlands) Besser et al. also noted that TG could be useful in risk stratification of patients for recurrent VTE [56]. In a prospective cohort of 188 patients with a first episode of unprovoked VTE or VTE provoked by a non-surgical trigger, the authors noted that patients with a high endogenous thrombin potential (ETP) (above the 50th percentile) had a significantly higher rate of unprovoked recurrence than those with a low ETP (below the 50th percentile) (HR 2.9, 95 % CI , cumulative recurrence at 4 years 27 vs. 11 %). A high ETP remained a significant predictor of recurrent VTE even after adjustment for D dimer level, presence of thrombophilia, sex and whether or not the first event was unprovoked (HR 2.6, 95 % CI ) [56]. In a prospective study of 254 patients after a first episode of unprovoked VTE, Tripodi et al. found that patients with ETP of greater than 960 nm times minutes or peak TG greater than 193 nm measured in the presence of thrombomodulin had hazard ratios (HR) for recurrent VTE of 3.41 (95 % CI ) and 4.57 (95 % CI ), respectively as compared with those with an ETP less than 563 nm times minutes or peak TG of less than 115 nm [57]. Tests performed in the absence of thrombomodulin were less predictive of recurrence risk. These papers establish that various laboratory parameters associated with measurement of endogenous thrombin potential are associated with the risk of recurrent VTE. A limitation of all these studies is the technical nature of thrombin generation assays which at the present do not lend themselves to use in routine clinical laboratories. Several other global laboratory assays have been examined in risk stratification of patients for recurrent VTE. Patients with an aptt ratio C0.95 had a relative risk of recurrent VTE of 0.58 (95 % CI , p = 0.009) after adjustment for sex, age, FVL and PGM compared to patients with an APTT ratio \0.95 [58]. Among patients with P selectin levels above the 75 percentile for the population, the probability of recurrence after 4 years of follow up was 20.6 % (95 % CI ) versus 10.8 % (95 % CI ) among patients with lower values for an adjusted risk of recurrence of 1.7-fold (95 % CI , p = 0.045) [59]. Multivariable models for risk assessment of recurrent VTE The ideal approach to developing a risk assessment model for recurrent VTE would be based upon prospective observation of a large population of well characterized patients with VTE. Several risk assessment models have taken this approach. The first study to take this approach was that published by Marc Rodger and colleagues in 2009 in the Canadian Medical Association Journal [10]. In a multicenter prospective study, they enrolled 646 patients with a first episode of unprovoked symptomatic VTE. They defined unprovoked venous thromboembolism as one that occurred in the absence of a leg fracture or plaster cast, immobilization or surgery within 3 months and no history of cancer within 5 years. They collected demographic, clinical and laboratory data on 69 potential predictors of recurrent VTE during 5 7 months of anticoagulation. D dimer and select thrombophilia testing was performed during therapy. After completion of therapy, participants were seen every 6 months for a mean duration of 18 months (range 1 47). Six hundred of 665 participants completed follow up. Ninety-one objectively documented episodes of VTE occurred for a 9.3 % annual risk of recurrence (95 % CI %). No fatal episodes of VTE occurred. The annual risk of recurrent VTE was higher among men (13.7 %; 95 % CI %) than women (5.5 %; 95 % CI %). Men with signs and symptoms of post-thrombotic syndrome had an especially high annual risk of recurrence (24 %). With the available data set of clinical and demographic variables, the authors were able to identify a subgroup of women with a low annual risk of recurrence (Table 3). This model identified 52.2 %

Duration of Therapy for Venous Thromboembolism

Duration of Therapy for Venous Thromboembolism Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee

More information

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis

More information

Thrombophilia: To test or not to test

Thrombophilia: To test or not to test Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical

More information

Choosing Wisely: If, When, What, and Who to Test for Thrombophilia

Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Nicole Dodge Zantek, MD, PhD Medical Director, Special Coagulation Laboratory University of Minnesota Disclosures Financial interests

More information

Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI

Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri

More information

How long to continue anticoagulation after DVT?

How long to continue anticoagulation after DVT? How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in

More information

Mabel Labrada, MD Miami VA Medical Center

Mabel Labrada, MD Miami VA Medical Center Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and

More information

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE

More information

UC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE

UC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism

More information

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?

More information

Approach to Thrombosis

Approach to Thrombosis Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation

More information

Duration of anticoagulation

Duration of anticoagulation Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,

More information

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be

More information

Menopausal Hormone Therapy & Haemostasis

Menopausal Hormone Therapy & Haemostasis Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen

More information

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase

More information

Laboratory Evaluation of Venous Thrombosis Risk

Laboratory Evaluation of Venous Thrombosis Risk Laboratory Evaluation of Venous Thrombosis Risk Dorothy M. Adcock, MD Volume 17, Number 12 December 2003 Objective: The reader will be able to discuss the concepts of risk factor, risk potential and thrombotic

More information

Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE

Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion:

More information

Are there still any valid indications for thrombophilia screening in DVT?

Are there still any valid indications for thrombophilia screening in DVT? Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016

More information

Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism

Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism ARTICLES Coagulation & its Disorders Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism Tom van der Hulle, Melanie Tan, Paul L. den Exter, Mark J.G.

More information

The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study

The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study Journal of Thrombosis and Haemostasis, 12: 635 640 DOI: 10.1111/jth.12528 ORIGINAL ARTICLE The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study

More information

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:

More information

Venous Thromboembolic Disease Update

Venous Thromboembolic Disease Update Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada

More information

Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism

Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism

More information

Scott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine

Scott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine Scott M. Stevens, MD Co-Director, Thrombosis Clinic Intermountain Medical Center Associate Professor of Clinical Medicine The University of Utah School of Medicine No Relevant Financial Relationships Research

More information

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)

More information

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer

More information

Chapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families

Chapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Chapter A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Willem M. Lijfering Nic J.G.M. Veeger Saskia Middeldorp Karly Hamulyák Martin

More information

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following

More information

ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation

ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of

More information

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:

More information

After a first episode of acute venous thromboembolism

After a first episode of acute venous thromboembolism Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia Gualtiero

More information

Updates in Diagnosis & Management of VTE

Updates in Diagnosis & Management of VTE Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE

More information

DEEP VEIN THROMBOSIS (DVT): TREATMENT

DEEP VEIN THROMBOSIS (DVT): TREATMENT DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada

More information

WGA meeting Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège

WGA meeting Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège WGA meeting 2016 Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège Clinical question Which complementary investigations are you going to plan during or early after hospitalization

More information

Should Patients with Venous Thromboembolism Be Screened for Thrombophilia?

Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? REVIEW Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? James E. Dalen, MD, MPH University of Arizona, Tucson. ABSTRACT In the mid-19th century, Virchow identified hypercoagulability

More information

Epidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione

Epidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Epidemiologia e clinica del tromboembolismo venoso Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Thrombophilia may present clinically as one or more of several thrombotic manifestations

More information

CANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital

CANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened

More information

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)

More information

Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren

Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker

More information

Paolo Prandoni Università di Padova

Paolo Prandoni Università di Padova Paolo Prandoni Università di Padova Il domani doloroso della TVP FCSA, Bologna 2014 Teatro Anatomico Università di Padova Eventi attesi a distanza da un evento tromboembolico venoso Recidiva di TEV PTS

More information

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital

More information

Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust

Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust MANAGEMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) IN THE COMMUNITY SETTING & ANTICOAGULATION CLINICS THE PAST, PRESENT AND THE FUTURE Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous

More information

Thrombosis. By Dr. Sara Mohamed Abuelgasim

Thrombosis. By Dr. Sara Mohamed Abuelgasim Thrombosis By Dr. Sara Mohamed Abuelgasim 1 Thrombosis Unchecked, blood coagulation would lead to dangerous occlusion of blood vessels if the protective mechanisms of coagulation factor inhibitors, blood

More information

Cancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School

Cancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School Cancer Associated Thrombosis: six months and beyond Farzana Haque Hull York Medical School Disclosure I have no disclosure The Challenge of Anticoagulation in Patients with Venous Thromboembolism and Cancer

More information

THROMBOSIS RISK FACTOR ASSESSMENT

THROMBOSIS RISK FACTOR ASSESSMENT Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)

More information

VTE in Children: Practical Issues

VTE in Children: Practical Issues VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.

More information

Original Policy Date

Original Policy Date MP 2.04.71 Genetic Testing for Inherited Thrombophilia Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search12:2013 Return to

More information

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational

More information

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior

More information

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior

More information

THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO

THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective

More information

CHAPTER 2 VENOUS THROMBOEMBOLISM

CHAPTER 2 VENOUS THROMBOEMBOLISM CHAPTER 2 VENOUS THROMBOEMBOLISM Objectives Venous Thromboembolism (VTE) Prevalence Patho-physiology Risk Factors Diagnosis Pulmonary Embolism (PE) Management of DVT/PE Prevention VTE Patho-physiology

More information

THROMBOPHILIA SCREENING

THROMBOPHILIA SCREENING THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis

More information

Optimal Utilization of Thrombophilia Testing

Optimal Utilization of Thrombophilia Testing Optimal Utilization of Thrombophilia Testing Rajiv K. Pruthi, MBBS Special Coagulation Laboratory & Comprehensive Hemophilia Center Division of Hematology/Internal Medicine Dept of Laboratory Medicine

More information

Diagnosis and management of heritable thrombophilias

Diagnosis and management of heritable thrombophilias Link to this article online for CPD/CME credits Diagnosis and management of heritable thrombophilias Peter MacCallum, 1 2 Louise Bowles, 2 David Keeling 3 1 Wolfson Institute of Preventive Medicine, Barts

More information

Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005

Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005 Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.

More information

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM

More information

Venous thromboembolism (VTe) affects approximately

Venous thromboembolism (VTe) affects approximately The Journal of The american osteopathic association Duration of Anticoagulation Treatment in Patients With Venous Thromboembolism Scott Kaatz, DO, MSc; Waqas Qureshi, MD; Christopher Fain, DO; and David

More information

PE service. 65 years old lady. What would you do next? Risk stratification. What would you do next? Regional College Lecture PE Management

PE service. 65 years old lady. What would you do next? Risk stratification. What would you do next? Regional College Lecture PE Management PE service Regional College Lecture PE Management Update in medicine (Eastern) Cambridge 29 th June 2017 Dr Rachel M Limbrey DM FRCP University Hospital Southampton NHS Foundation Trust Ambulatory acute

More information

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Dorothy M. (Adcock) Funk, M.D. Karen A. Moser, M.D. Esoterix Coagulation September 20, 2013 Disclosures

More information

Pulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical

Pulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical Pulmonary embolus - a practical approach to investigation and treatment Sam Janes Wellcome Senior Fellow and Respiratory Physician, University College London Background Diagnosis Treatment Common: 50 cases

More information

Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data COPYRIGHT. Kenneth A.

Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data COPYRIGHT. Kenneth A. Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data Kenneth A. Bauer, MD kbauer@bidmc.harvard.edu Disclosures Janssen rivaroxaban BMS apixaban Boehringer

More information

CLINICIANS TEST FOR PROTHROMbotic

CLINICIANS TEST FOR PROTHROMbotic CLINICAL REVIEW CLINICIAN S CORNER Predictive Value of Factor V Leiden and Prothrombin G20210A in Adults With Venous Thromboembolism and in Family Members of Those With a Mutation A Systematic Review Jodi

More information

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine

More information

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the

More information

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew

More information

Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium

Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,

More information

Prevention and management of venous thromboembolism M. AAPRO

Prevention and management of venous thromboembolism M. AAPRO Prevention and management of venous thromboembolism M. AAPRO Thromboprophylaxisof DVT and PE in AmbulatoryCancerPatients Zurich, February 2017 M. AAPRO Based on a lesson in April 2016 by M. DICATO M.D.,

More information

Venous Thrombosis in Asia

Venous Thrombosis in Asia Venous Thrombosis in Asia Pantep Angchaisuksiri, M.D. Professor of Medicine, Mahidol University, Thailand Adjunct Associate Professor, University of North Carolina, Chapel Hill, USA Venous Thromboembolism

More information

Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden

Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden Inaugural meeting of Iranian Society on Thrombosis and Haemostasis Mofid Children Hospital Tehran, 24 December 2015 Chest. 2012;141(2_suppl):e48S-e801S

More information

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular

More information

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic

More information

THROMBOTIC DISORDERS: The Final Frontier

THROMBOTIC DISORDERS: The Final Frontier THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 16 December 1999 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA) Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology

More information

THE INCIDENCE RATE OF A FIRST

THE INCIDENCE RATE OF A FIRST ORIGINAL CONTRIBUTION Thrombophilia, Clinical Factors, and Recurrent Venous Thrombotic Events Sverre C. Christiansen, MD Suzanne C. Cannegieter, MD, PhD Ted Koster, MD, PhD Jan P. Vandenbroucke, MD, PhD

More information

Il D-dimero: vantaggi e limiti

Il D-dimero: vantaggi e limiti XXVI Congresso Nazionale FCSA Bologna 5-7 Novembre 2015 Il D-dimero: vantaggi e limiti Gualtiero Palareti Cardiovascular diseases University of Bologna, Italy Degradation of stabilized fibrin DD= Methodolgical

More information

Prevention and treatment of venous thromboembolic disease

Prevention and treatment of venous thromboembolic disease REVIEW Prevention and treatment of venous thromboembolic disease SUSAN McNEILL AND CATHERINE BAGOT Awareness of the risk factors for venous thromboembolic (VTE) disease and timely administration of thromboprophylaxis

More information

Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017

Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017 Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in

More information

This chapter will describe the effectiveness of antithrombotic

This chapter will describe the effectiveness of antithrombotic Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,

More information

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness

More information

Potpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy

Potpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy Potpourri of Hematology Oncology Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy Lifestyle Modifications to Decrease the Risk of Colorectal Cancer Estimates for 2018 American

More information

Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD

Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD Thrombosis II Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD Inherited Risk Factors for Venous Thrombosis Mary Cushman Venous

More information

Tabac et Maladie Veineuse Thrombo-Embolique. Antoine ELIAS Hôpital Sainte Musse Toulon Novembre 2018

Tabac et Maladie Veineuse Thrombo-Embolique. Antoine ELIAS Hôpital Sainte Musse Toulon Novembre 2018 Tabac et Maladie Veineuse Thrombo-Embolique Antoine ELIAS Hôpital Sainte Musse Toulon Novembre 2018 Tabac: Facteur de risque de MTEV? Tabac - Thrombose Veineuse Association? Force de l association? Association

More information

New Developments in VTE Treatment

New Developments in VTE Treatment Disclosures: Accommodation at this meeting funded by Boehringer Investigator in phase III studies of Rivaroxiban, Dabigatran, Edoxaban New Developments in VTE Treatment GPCME meeting, August, Dunedin Dr

More information

Thromboembolism and cancer: New practices. Marc Carrier

Thromboembolism and cancer: New practices. Marc Carrier Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant

More information

Duration of Anticoagulation: Applying the Guidelines and Beyond

Duration of Anticoagulation: Applying the Guidelines and Beyond ISSUES IN THROMBOSIS MANAGEMENT AND ANTICOAGULATION Duration of Anticoagulation: Applying the Guidelines and Beyond Kenneth A. Bauer 1,2 1 Hematology Section, VA Boston Healthcare System and Beth Israel

More information

Citation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. [Groningen]: Rijksuniversiteit Groningen.

Citation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. [Groningen]: Rijksuniversiteit Groningen. University of Groningen The pill and thrombosis van Vlijmen, Elizabeth Femma Willemien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.

More information

PROGNOSIS AND SURVIVAL

PROGNOSIS AND SURVIVAL CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link

More information

Cancer associated thrombosis. 17 th November 2016 Simon Noble Clinical Professor Palliative Medicine Cardiff University Wales, UK

Cancer associated thrombosis. 17 th November 2016 Simon Noble Clinical Professor Palliative Medicine Cardiff University Wales, UK Cancer associated thrombosis 17 th November 2016 Simon Noble Clinical Professor Palliative Medicine Cardiff University Wales, UK Today What is VTE? How does CAT differ? Initial anticoagulation Anticoagulation

More information

DOACs in SPECIAL POPULATIONS

DOACs in SPECIAL POPULATIONS DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy

More information

Understanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal

Understanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria

More information

DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University

DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US

More information

Medical Patients: A Population at Risk

Medical Patients: A Population at Risk Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well

More information

Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum

Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Online Data Supplement Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Stacey M. Kassutto, C. Jessica Dine, Maryl Kreider, Rupal

More information

Thrombophilias: A Practical Approach

Thrombophilias: A Practical Approach Disclosures Thrombophilias: A Practical Approach Speaker s Bureau: BMS/Pfizer (Apixaban) PI Altru Health System: EVE Trial Apixaban in Malignancy Keith E Swanson MD North Dakota Family Medicine Conference,

More information

Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE

Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE To cite: Ensor J, Riley RD, Moore D, et al. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open 2016;6:e011190. doi:10.1136/bmjopen-2016-011190

More information

Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH. Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD

Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH. Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH TO T HROMBOPHILIA W ORKUPS & FRESH F ROZEN P LASMA U SE Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD Learning Objectives AFTER COMPLETION

More information

Venous thrombosis in unusual sites

Venous thrombosis in unusual sites Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers

More information